Jefferies Group restated their buy rating on shares of Cooper Companies (NYSE:COO) in a report published on Friday morning. The firm currently has a $285.00 price objective on the medical device company’s stock. Jefferies Group also issued estimates for Cooper Companies’ Q2 2018 earnings at $2.85 EPS, Q3 2018 earnings at $3.27 EPS, Q4 2018 earnings at $2.94 EPS, FY2018 earnings at $11.85 EPS and FY2019 earnings at $12.70 EPS.
A number of other brokerages have also issued reports on COO. Stifel Nicolaus reiterated a buy rating and issued a $265.00 target price (down previously from $275.00) on shares of Cooper Companies in a research report on Friday, December 8th. Cleveland Research lowered shares of Cooper Companies from a buy rating to a hold rating in a research report on Friday, February 9th. Oppenheimer set a $250.00 target price on shares of Cooper Companies and gave the company a hold rating in a research report on Friday, December 8th. Raymond James Financial reiterated a buy rating and issued a $265.00 target price on shares of Cooper Companies in a research report on Monday, December 4th. Finally, Zacks Investment Research upgraded shares of Cooper Companies from a hold rating to a buy rating and set a $257.00 target price for the company in a research report on Tuesday, November 14th. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $267.50.
Cooper Companies (NYSE:COO) traded up $2.85 during trading on Friday, hitting $251.43. 1,196,670 shares of the stock traded hands, compared to its average volume of 388,848. The company has a market capitalization of $12,185.74, a price-to-earnings ratio of 72.04, a P/E/G ratio of 1.99 and a beta of 0.61. The company has a quick ratio of 1.26, a current ratio of 2.41 and a debt-to-equity ratio of 0.36. Cooper Companies has a fifty-two week low of $192.24 and a fifty-two week high of $260.26.
The firm also recently declared a semiannual dividend, which was paid on Friday, February 9th. Shareholders of record on Tuesday, January 23rd were issued a $0.03 dividend. This represents a yield of 0.03%. The ex-dividend date was Monday, January 22nd. Cooper Companies’s payout ratio is 1.72%.
In other Cooper Companies news, Director A Thomas Bender sold 9,150 shares of the company’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $229.17, for a total value of $2,096,905.50. Following the completion of the sale, the director now directly owns 11,205 shares of the company’s stock, valued at approximately $2,567,849.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary S. Petersmeyer sold 785 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $229.06, for a total transaction of $179,812.10. The disclosure for this sale can be found here. Insiders sold a total of 54,385 shares of company stock valued at $12,289,463 over the last three months. 1.60% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Xact Kapitalforvaltning AB lifted its stake in Cooper Companies by 3.3% during the fourth quarter. Xact Kapitalforvaltning AB now owns 13,701 shares of the medical device company’s stock valued at $2,985,000 after buying an additional 444 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in Cooper Companies by 8.3% during the fourth quarter. Handelsbanken Fonder AB now owns 325,400 shares of the medical device company’s stock valued at $70,898,000 after buying an additional 25,000 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in Cooper Companies by 9.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 10,113 shares of the medical device company’s stock valued at $2,205,000 after buying an additional 850 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in Cooper Companies by 7.0% during the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 21,374 shares of the medical device company’s stock valued at $4,657,000 after buying an additional 1,395 shares in the last quarter. Finally, We Are One Seven LLC purchased a new stake in Cooper Companies during the fourth quarter valued at about $351,000. 97.45% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This news story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3253342/cooper-companies-coo-buy-rating-reiterated-at-jefferies-group.html.
About Cooper Companies
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.